Can TTP be cured outright? Not for most patients, but modern therapy converts a once-fatal illness into a survivable and often controllable one. Immune TTP reaches durable remission in roughly half to two-thirds of patients after plasma exchange, steroids, and rituximab. Congenital TTP instead requires lifelong replacement therapy. Roughly one in ten immune cases still dies during the acute episode, usually when diagnosis is delayed. In plain terms: TTP is highly treatable, frequently controllable, and only sometimes cured.
The Mechanism: What ADAMTS13 Loss Does to Blood
ADAMTS13 is a protease made mainly by hepatic stellate cells and, in smaller amounts, by endothelial cells. Its circulating activity in healthy adults runs 50 to 100 percent of a standardized normal. Its only meaningful job is cutting von Willebrand factor.
Von Willebrand factor leaves endothelial cells as ultra-large multimers, some approaching 20,000 kDa. In that unfolded state, the A1 domain is exposed and binds platelet glycoprotein Ibα directly. ADAMTS13 cleaves a single peptide bond, Tyr1605–Met1606, inside the A2 domain. That cut trims the multimers down to 500–2,000 kDa and sets their half-life at roughly 12 hours.
Remove that cut, and the biology changes character. Ultra-large multimers stay anchored to endothelium and stay open. Platelets adhere without any vessel injury. Strings of platelet-decorated multimers build in arterioles and capillaries, and red cells passing through them fracture.
The downstream numbers are characteristic. Platelets fall below 30,000/µL in more than 90 percent of acute cases, often to 10,000–20,000/µL. Schistocytes appear at 1 to 5 percent of red cells. Lactate dehydrogenase typically runs 1,000–2,000 U/L as sheared cells release their contents. Haptoglobin becomes undetectable.
Ischemia follows the clot distribution. Neurologic signs appear in about 60 percent of patients at presentation. Renal involvement occurs in 20 to 30 percent, and cardiac ischemia is found in a smaller but clinically important fraction.
The mechanistic point that changes management: TTP is a loss-of-function protease deficiency, not an excess of a clotting factor. Heparin has no target here. Platelet transfusions add fuel to a fire that is already platelet-driven, which is why they are withheld unless there is life-threatening bleeding.
Can TTP Be Cured by Restoring ADAMTS13?
Every effective therapy works by one of three routes: removing the autoantibody, supplying the missing enzyme, or blocking the downstream platelet adhesion. None of them repairs the underlying defect permanently in every patient.
Plasma exchange does the first two at once. A single exchange of 1.0 to 1.5 plasma volumes, roughly 40–60 mL/kg, removes circulating antibody and ultra-large multimers and replaces functional ADAMTS13 from donor plasma. Because antibody rebounds and infused enzyme has a short half-life, exchanges run daily.
Corticosteroids at 1 mg/kg/day of prednisone suppress new antibody production. They are a partner to exchange, not a replacement for it.
Rituximab, dosed at 375 mg/m² weekly for four weeks, depletes B cells and lowers antibody production over two to six weeks. That delay is the point: ADAMTS13 recovery lags platelet recovery by weeks, so rituximab is started early in relapsing or refractory disease rather than withheld as a rescue.
Caplacizumab is a bivalent nanobody that binds the vWF A1 domain and blocks platelet GPIbα engagement. In the HERCULES trial reported by Scully and colleagues in 2019, the composite of TTP-related death, exacerbation, or major thromboembolic event fell to 12 percent from 38 percent. Bleeding events were roughly 1.5 times more common, and nearly two-thirds of recipients had at least one.
That last drug hides a trap. Caplacizumab normalizes the platelet count while ADAMTS13 may still sit below 10 percent. The blood looks cured while the mechanism is untouched. Stopping the drug too early, or stopping monitoring, produces relapse.
For congenital TTP, the enzyme itself is missing for life. Plasma infusion at 10–15 mL/kg every two to three weeks supplies it, and recombinant ADAMTS13 approved by the FDA in 2024 offers a non-plasma alternative for prophylaxis. Splenectomy remains a durable option for the roughly 10 to 20 percent of immune cases that stay refractory, producing long-term remission in 70 to 80 percent of selected patients.
The Numbers: Mortality and Remission Rates
Historical figures are stark. Before plasma exchange, untreated TTP killed 80 to 90 percent of patients, often within days.
The 1991 randomized trial that established exchange as standard care reported survival of 78 percent with plasma exchange versus 63 percent with plasma infusion alone. Modern referral-center series now report acute mortality of 5 to 15 percent. The apparent conflict between a 90 percent historical death rate and a 5 to 15 percent current one is almost entirely a story about plasma exchange, with earlier diagnosis and caplacizumab accounting for more recent gains.
Remission is the common outcome, cure is not. About 80 to 90 percent of immune TTP patients achieve remission with first-line therapy. Durability is where the word "cure" breaks down: 30 to 50 percent relapse within ten years, though many of those patients re-enter remission with retreatment.
One number needs reconciling against another. ADAMTS13 below 10 percent of normal is the diagnostic threshold for acute TTP, while activity below 20 percent is the threshold used to flag relapse risk. They are different cutoffs answering different questions, and a value of 15 percent is abnormal but not diagnostic on its own.
Timeline of an Acute TTP Episode
| Timeframe | What happens | Key numbers |
|---|---|---|
| Hour 0–6 | Presentation; ADAMTS13 sample drawn before any plasma | PLASMIC score of 6–7 predicts severe deficiency |
| Hour 6–24 | First plasma exchange plus corticosteroids | 1.0–1.5 plasma volumes (40–60 mL/kg); prednisone 1 mg/kg |
| Day 2–4 | Daily exchange; caplacizumab often added | Platelets commonly double within 48–72 hours |
| Day 5–7 | Response assessment | Exchange stopped after platelets above 150,000/µL on two consecutive days |
| Day 7–14 | Rituximab course and continued caplacizumab | 375 mg/m² weekly for four doses; caplacizumab for 30 days past last exchange |
| Week 3–6 | ADAMTS13 recheck | Target above 20 percent; below 10 percent signals high relapse risk |
| Month 3–24 | Structured surveillance | ADAMTS13 every three months for two years |
| Year 1–10 | Cumulative relapse window | 30–50 percent relapse; most occur in the first two years |
Immune vs Congenital TTP: Different Cures, Different Rules
| Feature | Immune TTP | Congenital TTP |
|---|---|---|
| Cause | Autoantibodies against ADAMTS13 | Biallelic ADAMTS13 gene variants |
| Share of adult cases | About 95 percent | About 5 percent |
| Typical onset | Ages 30–50, any age | Childhood or first pregnancy |
| Acute therapy | Exchange, steroids, rituximab, caplacizumab | Plasma infusion or recombinant ADAMTS13 |
| Maintenance | None in most patients | Prophylaxis every 2–3 weeks |
| Potential for cure | Durable remission off therapy in 50–70 percent | No cure; lifelong control |
| Relapse without prophylaxis | 30–50 percent at ten years | Near-universal |
The congenital form is the clearer case for the word "curable." It is not. A patient with biallelic ADAMTS13 variants produces almost no functional enzyme and will need replacement indefinitely. What has changed since 2024 is convenience and safety, not curability.
The immune form is the opposite. It is acquired, potentially transient, and sometimes disappears for good. Roughly half to two-thirds of patients stop all therapy and stay in remission for years.
Relapse and Three Common Misconceptions
Relapse terminology matters clinically. An exacerbation is a recurrence within 30 days of the first response and reflects incomplete antibody suppression. A relapse occurs after 30 days. Exacerbations run about 10 to 20 percent in exchange-treated patients and are lower with caplacizumab. Relapses accumulate to 30 to 50 percent over ten years, with the steepest slope in the first 24 months.
Persistent ADAMTS13 activity below 20 percent after rituximab raises relapse risk roughly two- to three-fold. That single number drives most modern monitoring schedules.
First misconception: a normal platelet count means cured. ADAMTS13 can sit below 10 percent for months while platelets remain normal, because the antibody burden fluctuates. The patient is biochemically smoldering, not cured.
Second misconception: platelet transfusion is a safe supportive measure. In TTP it feeds the microthrombotic process and can precipitate neurologic or cardiac deterioration. It is reserved for life-threatening bleeding or before an urgent procedure.
Third misconception: TTP is a variant of disseminated intravascular coagulation or hemolytic uremic syndrome. Coagulation times are typically normal in TTP, fibrinogen is normal, and heparin does nothing. Confusing the three delays the one therapy that works.
An edge case worth knowing: drug-induced TTP from ticagrelor or immune checkpoint inhibitors behaves differently from idiopathic disease and often resolves after the drug is withdrawn. Pregnancy-triggered congenital TTP is another, and it is frequently the first manifestation in women who have gone undiagnosed for decades.
What to Actually Do, and the Limits
The highest-value action is diagnostic sequencing. Draw the ADAMTS13 sample before any plasma is given, because a single exchange can push activity above the diagnostic threshold and erase the evidence. Then move the patient to a center with apheresis capability the same day.
Ask specifically about caplacizumab and rituximab rather than assuming standard triple therapy is the ceiling of care. Both change outcomes, and both are underused outside specialist centers.
Red flags that should trigger immediate reassessment:
- New confusion, severe headache, seizure, or focal weakness
- Chest pain or shortness of breath at rest
- Petechiae or bruising accompanied by fever
- Dark urine or falling urine output
- Platelets under 30,000/µL with schistocytes on the smear
- Unexpected bruising or bleeding while on caplacizumab
After remission, the practical schedule is ADAMTS13 testing every three months for two years, then annually, with immediate testing at any relapse of symptoms. Patients whose activity stays below 20 percent are candidates for preventive rituximab rather than watchful waiting.
The limits are real and worth stating plainly. No trial has established a validated rule for when it is safe to stop monitoring. Caplacizumab costs roughly USD 200,000 per acute course in the United States, and access varies widely. Recombinant ADAMTS13 is approved only for congenital disease, not for immune TTP. And a substantial minority of patients relapse despite every intervention being delivered correctly.
The honest summary of whether TTP can be cured is this: the congenital form is controlled, not cured; the immune form is cured in a meaningful minority and controlled in most; and the acute death rate, once 80 to 90 percent, now sits near 10 percent in centers that move fast.